Healthcare / BiotechnologyShanghai
$36.09
-0.49 (-1.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-183.4M · quality 71.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.9%
↓Gross Margin
96.9%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+68.0%
FCF CAGR
—
FCF margin
-1857.8%
FCF / Net income
1.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.7M · net income $-128.8M · FCF $-161.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.7M | $8.7M | $3.9M | $5.2M | $1.8M |
| Net Income | $-128.8M | $-128.8M | $-211.9M | $-185.6M | $-173.8M |
| EBITDA | $-121.6M | $-121.6M | $-205.0M | $-178.3M | $-167.1M |
| EPS | -0.87 | -0.87 | -1.43 | -1.25 | -1.25 |
| Gross Margin | 96.9% | 96.9% | 99.0% | 97.9% | 99.4% |
| Operating Margin | -1689.4% | -1689.4% | -5729.6% | -4047.4% | -10693.6% |
| Net Margin | -1486.4% | -1486.4% | -5376.4% | -3548.8% | -9512.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.00 | 0.01 |
| Current Ratio | 6.89 | 6.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-161.0M | $-161.0M | $-205.3M | $-183.4M | $-150.2M |
| Returns | |||||
| ROE | -18.9% | -18.9% | -26.2% | -18.2% | -14.4% |
| Valuation | |||||
| P/B | 7.86 | 7.86 | 5.13 | 7.49 | 3.25 |
| Growth & Yield | |||||
| Revenue Growth | 119.9% | 119.9% | -24.6% | 186.2% | — |
| EPS Growth | 39.2% | 39.2% | -14.4% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.43 → -0.87
Residual
+7.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.